Univariate analysis on predictors of OS and EFS
| Variable . | OS . | EFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Pre-HSCT status | ||||||
| Age at HSCT | 1.05 | 0.91-1.15 | .402 | 1.03 | 0.93-1.11 | .453 |
| Bronchiectasis | 1.78 | 0.21-14.8 | .563 | 0.94 | 0.13-4.81 | .942 |
| Pneumatocele | 0.80 | 0.09-6.66 | .821 | 0.84 | 0.15-4.68 | .838 |
| Any parenchymal lung disease | 1.21 | 0.16-24.5 | .868 | 0.82 | 0.16-5.98 | .820 |
| Pulmonary fungal infection | 2.05 | 0.24-17.1 | .472 | 1.30 | 0.18-6.69 | .760 |
| Donor | ||||||
| Matched family | 1.00 | |||||
| Matched unrelated | 0.81 | 0.09-6.71 | .829 | 2.01 | 0.41-15.0 | .396 |
| Graft source | ||||||
| Marrow | 1.00 | |||||
| PBSC | 0.29 | 0.01-2.24 | .279 | 1.08 | 0.19-5.94 | .927 |
| Conditioning | ||||||
| Treosulfan | 1.00 | |||||
| Busulfan | 0.98 | 0.05-10.2 | .985 | 1.86 | 0.22-15.8 | .541 |
| Melphalan | 1.44 | 0.07-15.0 | .768 | 1.98 | 0.22-17.1 | .507 |
| Serotherapy | ||||||
| Alemtuzumab | 1.00 | |||||
| ATG | <0.01 | <0.01-2.22 | >.99 | 0.61 | 0.03-4.16 | .662 |
| Variable . | OS . | EFS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Pre-HSCT status | ||||||
| Age at HSCT | 1.05 | 0.91-1.15 | .402 | 1.03 | 0.93-1.11 | .453 |
| Bronchiectasis | 1.78 | 0.21-14.8 | .563 | 0.94 | 0.13-4.81 | .942 |
| Pneumatocele | 0.80 | 0.09-6.66 | .821 | 0.84 | 0.15-4.68 | .838 |
| Any parenchymal lung disease | 1.21 | 0.16-24.5 | .868 | 0.82 | 0.16-5.98 | .820 |
| Pulmonary fungal infection | 2.05 | 0.24-17.1 | .472 | 1.30 | 0.18-6.69 | .760 |
| Donor | ||||||
| Matched family | 1.00 | |||||
| Matched unrelated | 0.81 | 0.09-6.71 | .829 | 2.01 | 0.41-15.0 | .396 |
| Graft source | ||||||
| Marrow | 1.00 | |||||
| PBSC | 0.29 | 0.01-2.24 | .279 | 1.08 | 0.19-5.94 | .927 |
| Conditioning | ||||||
| Treosulfan | 1.00 | |||||
| Busulfan | 0.98 | 0.05-10.2 | .985 | 1.86 | 0.22-15.8 | .541 |
| Melphalan | 1.44 | 0.07-15.0 | .768 | 1.98 | 0.22-17.1 | .507 |
| Serotherapy | ||||||
| Alemtuzumab | 1.00 | |||||
| ATG | <0.01 | <0.01-2.22 | >.99 | 0.61 | 0.03-4.16 | .662 |
CI, confidence interval; HR, hazard ratio.